Project Grant 2538091
Award Date 7/1/26
Completion Date 12/31/26
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Costa, CA 92009, USA
Similar Awards
- Federal Grant Award Summary Endure Biotherapeutics, Inc. received a $392,827 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria (ENB) as a novel therapeutic approach for familial adenomatous polyposis (FAP). The award, effective August 5, 2025, with completion targeted for July 31, 2026, supports the advancement of the company's platform technology that engineers native gut bacteria to express...
- The U.S. National Science Foundation (NSF) awarded a $303,864 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics, Inc. (UEI N9FGZ15RQGJ4) located in Ladera Ranch, CA. The project aims to develop a platform for discovering therapeutic drug candidates that can modulate molecular networks driving diseases, with the potential to produce disease-modifying effects for neurodegenerative...
- Federal Project Grant Summary Endura Therapeutics Inc. received a $303,445 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on May 15, 2025, with completion targeted for January 31, 2026. The award funds development of a next-generation sequencing-based platform designed to discover and screen small molecule drugs that target RNA. The primary deliverables include establishing...
- Federal Project Grant Summary Inphasol Inc. received a Project Grant award of $178,026 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop bacteriophage-based therapeutics targeting excessive hydrogen sulfide (H2S) production in the human gut microbiome. The project, titled "Phagineering the Gut Microbiome: Bacteriophages to Reduce Desulfovibrio spp. and...
- Biomesense Inc. received a $255,658 National Science Foundation SBIR Phase I Project Grant to develop a novel biosensor to accelerate investigations of COVID-19 and the gut microbiome. Funded under the NSF Engineering program (CFDA 47.041), this six-month award beginning January 15, 2021 supports the company's work to design a portable, low-cost biosensor device capable of rapidly detecting SARS-CoV-2 and analyzing gut microbiome composition directly from patient samples. The NSF Directorate for...
- This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $275,000 to Ubiquitx Inc., a New York-based small business, to develop a programmable, modular therapeutic platform for the direct modification of proteins of interest (POIs) using artificial intelligence, protein engineering, and mRNA therapeutics. The goal is to expand the applications of the company's Chimeric Ligands for Induced Proximity (CLIPS)...
- Federal Project Grant Award Summary Syntis Bio Inc. received a $324,984 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective August 1, 2025, through July 31, 2027. The company is developing an oral therapeutic platform to treat homocystinuria (HCU), a rare metabolic disorder caused by cystathionine-β-synthase enzyme deficiency. The core...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award for $997,142 aims to develop a rapid phenylalanine blood level monitor for patients with phenylketonuria (PKU), a lifelong genetic disorder. The product consists of a test strip and device that can provide frequent, accessible monitoring of phenylalanine levels from a finger prick to improve disease management and patient outcomes. The project focuses on optimizing the...
- This SBIR Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program seeks to develop a new class of gene therapies that can be delivered more safely, cost-effectively, and at scale for a wide range of serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible...
- Federal Grant Award Summary Award Details: Kapha Bio, Inc. received a $305,000 Project Grant from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on July 15, 2025, with a completion date of June 30, 2026. The company is located in Benicia, California. Products and Services: Under this Small Business Technology Transfer (STTR) Phase I award, Kapha Bio will develop a library of biomimetic mucins designed to address recurrent...